Sudden cardiac arrest

Summary

Sudden cardiac arrest (MONDO:0100511) is a disease with 7 cohort genes and 47 clinical trials. The dominant Reactome pathway is Cardiac conduction (3 cohort genes). Top therapeutic interventions include epinephrine, safflower oil, and sodium bicarbonate.

At a glance

• Cohort genes: 7
• ClinVar variants: 12
• Clinical trials: 47

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	sudden cardiac arrest
Mondo ID	MONDO:0100511
MeSH	C1720824
ICD-11	264292672
UMLS	C1720824
MedGen	354518
Is cancer (heuristic)	no

Data availability: 12 ClinVar variants.

Disease family

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › cardiac rhythm disease › sudden cardiac arrest

Related subtypes (16): ventricular fibrillation, cardiac arrest, atrial fibrillation, ventricular tachycardia, atrial tachycardia, torsade-de-pointes syndrome with short coupling interval, sinoatrial node dysfunction and deafness, sino-auricular heart block, multifocal atrial tachycardia, His bundle tachycardia, incessant infant ventricular tachycardia, ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome, sudden arrhythmia death syndrome, cardiac conduction defect, cardiac conduction disease with or without cardiomyoopathy, cardiogenetic rhythm disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

12 retrieved; paginated sample, class counts are floors:

6 uncertain significance, 3 conflicting classifications of pathogenicity, 2 benign/likely benign, 1 benign

ClinVar	Variant (HGVS)	Gene	Classification	Review
662181	NM_001148.6(ANK2):c.9116A>G (p.Asp3039Gly)	ANK2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
67769	NM_000335.5(SCN5A):c.2944T>C (p.Cys982Arg)	SCN5A	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
202343	NM_001267550.2(TTN):c.7628C>G (p.Thr2543Ser)	TTN	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
977179	NM_000238.4(KCNH2):c.1982C>T (p.Ala661Val)	KCNH2	Uncertain significance	no assertion criteria provided
453215	NM_001035.3(RYR2):c.8414G>A (p.Arg2805His)	RYR2	Uncertain significance	criteria provided, multiple submitters, no conflicts
633412	NM_000335.5(SCN5A):c.2182G>A (p.Val728Ile)	SCN5A	Uncertain significance	criteria provided, multiple submitters, no conflicts
977183	NM_000335.5(SCN5A):c.1672C>T (p.His558Tyr)	SCN5A	Uncertain significance	criteria provided, multiple submitters, no conflicts
922311	NM_000363.5(TNNI3):c.500T>C (p.Leu167Pro)	TNNI3	Uncertain significance	criteria provided, multiple submitters, no conflicts
202800	NM_001267550.2(TTN):c.66568G>C (p.Gly22190Arg)	TTN	Uncertain significance	criteria provided, multiple submitters, no conflicts
177840	NM_024334.3(TMEM43):c.698A>G (p.Tyr233Cys)	TMEM43	Benign	criteria provided, multiple submitters, no conflicts
46156	NM_024334.3(TMEM43):c.953C>T (p.Ala318Val)	TMEM43	Benign/Likely benign	criteria provided, multiple submitters, no conflicts
202874	NM_001267550.2(TTN):c.76922G>A (p.Arg25641His)	TTN	Benign/Likely benign	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 34 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
RYR2	Orphanet:293888	Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
RYR2	Orphanet:293899	Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant
RYR2	Orphanet:293910	Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant
RYR2	Orphanet:3286	Catecholaminergic polymorphic ventricular tachycardia
SCN5A	Orphanet:101016	Romano-Ward syndrome
SCN5A	Orphanet:130	Brugada syndrome
SCN5A	Orphanet:1344	Isolated atrial standstill
SCN5A	Orphanet:154	Familial isolated dilated cardiomyopathy
SCN5A	Orphanet:166282	Hereditary sick sinus syndrome
SCN5A	Orphanet:228140	Idiopathic ventricular fibrillation
SCN5A	Orphanet:334	Hereditary atrial fibrillation
SCN5A	Orphanet:871	Hereditary progressive cardiac conduction defect
TNNI3	Orphanet:154	Familial isolated dilated cardiomyopathy
TNNI3	Orphanet:75249	Familial isolated restrictive cardiomyopathy
TTN	Orphanet:140922	Titin-related limb-girdle muscular dystrophy R10
TTN	Orphanet:154	Familial isolated dilated cardiomyopathy
TTN	Orphanet:169186	Autosomal recessive centronuclear myopathy
TTN	Orphanet:178464	Hereditary myopathy with early respiratory failure
TTN	Orphanet:289377	Early-onset myopathy with fatal cardiomyopathy
TTN	Orphanet:293888	Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
TTN	Orphanet:293899	Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant
TTN	Orphanet:293910	Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant
TTN	Orphanet:324604	Classic multiminicore myopathy
TTN	Orphanet:334	Hereditary atrial fibrillation
TTN	Orphanet:466921	Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome
TTN	Orphanet:609	Tibial muscular dystrophy
TTN	Orphanet:707983	Early-onset autosomal recessive TTN-related distal myopathy
TMEM43	Orphanet:293888	Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
TMEM43	Orphanet:293899	Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant
TMEM43	Orphanet:293910	Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant
TMEM43	Orphanet:98853	Autosomal dominant Emery-Dreifuss muscular dystrophy
ANK2	Orphanet:101016	Romano-Ward syndrome
KCNH2	Orphanet:101016	Romano-Ward syndrome
KCNH2	Orphanet:51083	Congenital short QT syndrome

Cohort genes → proteins

7 cohort genes, 7 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	7

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
RYR2	HGNC:10484	ENSG00000198626	Q92736	Ryanodine receptor 2	clinvar
SCN5A	HGNC:10593	ENSG00000183873	Q14524	Sodium channel protein type 5 subunit alpha	clinvar
TNNI3	HGNC:11947	ENSG00000129991	P19429	Troponin I, cardiac muscle	clinvar
TTN	HGNC:12403	ENSG00000155657	Q8WZ42	Titin	clinvar
TMEM43	HGNC:28472	ENSG00000170876	Q9BTV4	Transmembrane protein 43	clinvar
ANK2	HGNC:493	ENSG00000145362	Q01484	Ankyrin-2	clinvar
KCNH2	HGNC:6251	ENSG00000055118	Q12809	Voltage-gated inwardly rectifying potassium channel KCNH2	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
RYR2	Ryanodine receptor 2	Cytosolic calcium-activated calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytosol and thereby plays a key role in triggering cardiac muscle contraction.
SCN5A	Sodium channel protein type 5 subunit alpha	Pore-forming subunit of Nav1.5, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes.
TNNI3	Troponin I, cardiac muscle	Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.
TTN	Titin	Key component in the assembly and functioning of vertebrate striated muscles.
TMEM43	Transmembrane protein 43	May have an important role in maintaining nuclear envelope structure by organizing protein complexes at the inner nuclear membrane.
ANK2	Ankyrin-2	Plays an essential role in the localization and membrane stabilization of ion transporters and ion channels in several cell types, including cardiomyocytes, as well as in striated muscle cells.
KCNH2	Voltage-gated inwardly rectifying potassium channel KCNH2	Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel.

Protein-family classification

Druggable: 4 · Difficult: 1 · Unknown: 2 · Druggable fraction: 0.57

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Ion channel	3	47.8×	1e-04
Kinase	1	4.0×	0.454
Scaffold/PPI	1	2.5×	0.455
Other/Unknown	2	0.5×	0.968

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
RYR2	Ion channel	yes		RIH_dom, B30.2/SPRY, EF_hand_dom
SCN5A	Ion channel	yes		Na_channel_asu, Ion_trans_dom, Na_channel_a5su
TNNI3	Other/Unknown	no		Troponin, Troponin-I_N, Troponin_sf
TTN	Kinase	yes	2.7.11.1	Prot_kinase_dom, Ig_sub2, Ig_sub
TMEM43	Other/Unknown	no		TMEM43_fam
ANK2	Scaffold/PPI	no		Death_dom, ZU5_dom, Ankyrin_rpt
KCNH2	Ion channel	yes		PAS, cNMP-bd_dom, PAS-assoc_C

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	7
unknown	0

Top tissues across cohort

Tissue	Cohort genes
apex of heart	3
left ventricle myocardium	2
right atrium auricular region	2
heart right ventricle	1
myocardium	1
cardiac ventricle	1
heart left ventricle	1
biceps brachii	1
gluteal muscle	1
skeletal muscle tissue of biceps brachii	1
ascending aorta	1
descending thoracic aorta	1
thoracic aorta	1
lateral nuclear group of thalamus	1
substantia nigra pars compacta	1
substantia nigra pars reticulata	1
cardiac atrium	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
RYR2	210	broad	marker	heart right ventricle, left ventricle myocardium, myocardium
SCN5A	161	broad	yes	apex of heart, heart left ventricle, cardiac ventricle
TNNI3	169	broad	marker	apex of heart, left ventricle myocardium, right atrium auricular region
TTN	223	broad	marker	biceps brachii, gluteal muscle, skeletal muscle tissue of biceps brachii
TMEM43	287	ubiquitous	marker	descending thoracic aorta, thoracic aorta, ascending aorta
ANK2	281	ubiquitous	marker	substantia nigra pars compacta, lateral nuclear group of thalamus, substantia nigra pars reticulata
KCNH2	211	broad	marker	apex of heart, right atrium auricular region, cardiac atrium

Protein interactions among cohort

Intra-cohort edges: 4.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
ANK2	6,423
TTN	4,237
RYR2	2,653
SCN5A	2,090
KCNH2	1,932
TMEM43	1,864
TNNI3	1,836

Intra-cohort edges

A	B	Sources
ANK2	TTN	string_interaction
KCNH2	SCN5A	string_interaction
RYR2	TMEM43	string_interaction
TNNI3	TTN	string_interaction

Structural data

PDB: 6 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
TTN	Q8WZ42	64
TNNI3	P19429	39
RYR2	Q92736	26
KCNH2	Q12809	24
SCN5A	Q14524	16
ANK2	Q01484	11

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
TMEM43	Q9BTV4	89.92

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 26. Enrichment computed across 7 evidence-associated genes (6 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Cardiac conduction	3	54.4×	4e-04	RYR2, SCN5A, KCNH2
Muscle contraction	3	38.6×	5e-04	RYR2, SCN5A, KCNH2
Interaction between L1 and Ankyrins	2	122.8×	9e-04	SCN5A, ANK2
Striated Muscle Contraction	2	102.9×	1e-03	TNNI3, TTN
Ion homeostasis	2	68.0×	0.002	RYR2, TNNI3
L1CAM interactions	2	40.1×	0.004	SCN5A, ANK2
Phase 3 - rapid repolarisation	1	190.3×	0.019	KCNH2
Axon guidance	2	15.1×	0.022	SCN5A, ANK2
Nervous system development	2	14.3×	0.022	SCN5A, ANK2
Phase 0 - rapid depolarisation	1	57.7×	0.045	SCN5A
Voltage gated Potassium channels	1	40.5×	0.058	KCNH2
Stimuli-sensing channels	1	22.7×	0.082	RYR2
Potassium Channels	1	22.4×	0.082	KCNH2
ER to Golgi Anterograde Transport	1	22.1×	0.082	ANK2
COPI-mediated anterograde transport	1	18.3×	0.088	ANK2
Transport to the Golgi and subsequent modification	1	17.1×	0.088	ANK2
Ion channel transport	1	16.0×	0.088	RYR2
Developmental Biology	2	4.8×	0.088	SCN5A, ANK2
Platelet degranulation	1	14.6×	0.091	TTN
Asparagine N-linked glycosylation	1	10.0×	0.125	ANK2
Neuronal System	1	7.4×	0.159	KCNH2
Membrane Trafficking	1	6.2×	0.179	ANK2
Vesicle-mediated transport	1	5.8×	0.181	ANK2
Transport of small molecules	1	4.2×	0.234	RYR2
Post-translational protein modification	1	3.2×	0.286	ANK2
Metabolism of proteins	1	2.1×	0.397	ANK2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
cardiac muscle contraction	5	286.6×	2e-10	RYR2, SCN5A, TNNI3, TTN, KCNH2
ventricular cardiac muscle cell action potential	4	566.5×	2e-09	RYR2, SCN5A, ANK2, KCNH2
regulation of cardiac muscle contraction by calcium ion signaling	3	555.6×	6e-07	RYR2, TNNI3, ANK2
regulation of ventricular cardiac muscle cell membrane repolarization	3	361.1×	2e-06	SCN5A, ANK2, KCNH2
regulation of heart rate	3	200.6×	9e-06	RYR2, SCN5A, ANK2
regulation of atrial cardiac muscle cell action potential	2	1605.0×	1e-05	RYR2, ANK2
regulation of heart rate by cardiac conduction	3	160.5×	1e-05	SCN5A, ANK2, KCNH2
sarcoplasmic reticulum calcium ion transport	2	963.0×	2e-05	RYR2, ANK2
membrane depolarization during SA node cell action potential	2	963.0×	2e-05	SCN5A, ANK2
SA node cell action potential	2	802.5×	3e-05	SCN5A, ANK2
regulation of SA node cell action potential	2	802.5×	3e-05	RYR2, ANK2
cardiac muscle hypertrophy	2	481.5×	7e-05	RYR2, TTN
membrane depolarization during action potential	2	481.5×	7e-05	SCN5A, KCNH2
atrial cardiac muscle cell action potential	2	481.5×	7e-05	SCN5A, ANK2
intracellular calcium ion homeostasis	3	62.3×	1e-04	RYR2, TNNI3, ANK2
regulation of cardiac muscle cell contraction	2	321.0×	1e-04	SCN5A, ANK2
muscle filament sliding	2	300.9×	1e-04	TNNI3, TTN
regulation of cardiac muscle contraction	2	253.4×	2e-04	RYR2, ANK2
striated muscle contraction	2	240.7×	2e-04	RYR2, TTN
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion	2	192.6×	3e-04	RYR2, ANK2
skeletal muscle contraction	2	145.9×	5e-04	TNNI3, TTN
sodium ion transport	2	77.7×	0.002	SCN5A, TMEM43
protein localization to T-tubule	1	2407.4×	0.002	ANK2
establishment of protein localization to endoplasmic reticulum	1	2407.4×	0.002	RYR2
atrial cardiac muscle cell to AV node cell communication	1	2407.4×	0.002	ANK2
SA node cell to atrial cardiac muscle cell communication	1	2407.4×	0.002	ANK2
potassium ion transport	2	54.7×	0.003	TMEM43, KCNH2
regulation of systemic arterial blood pressure by ischemic conditions	1	1203.7×	0.003	TNNI3
regulation of heart rate by hormone	1	1203.7×	0.003	KCNH2
positive regulation of cell communication by electrical coupling	1	1203.7×	0.003	TMEM43

Therapeutics

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 3 · Undrugged: 4

Druggability breadth: 6 of 7 evidence-associated genes (86%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
SCN5A	BEPRIDIL
KCNH2	CETIRIZINE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
KCNH2	706	4
SCN5A	108	4
RYR2	1	2
TNNI3	0	0
TTN	0	0
TMEM43	0	0
ANK2	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
BEPRIDIL	4	KCNH2, SCN5A
CANDESARTAN CILEXETIL	4	SCN5A
TELMISARTAN	4	SCN5A
CARBAMAZEPINE	4	SCN5A
DIBUCAINE	4	KCNH2, SCN5A
IMIPRAMINE	4	KCNH2, SCN5A
DROPERIDOL	4	KCNH2, SCN5A
PONATINIB	4	KCNH2, SCN5A
DULOXETINE	4	KCNH2, SCN5A
PALONOSETRON	4	KCNH2, SCN5A
VILANTEROL	4	SCN5A
MEXILETINE HYDROCHLORIDE	4	SCN5A
UNOPROSTONE ISOPROPYL	4	SCN5A
LURASIDONE	4	KCNH2, SCN5A
LETERMOVIR	4	SCN5A
SERTINDOLE	4	KCNH2, SCN5A
FEDRATINIB	4	KCNH2, SCN5A
QUINIDINE	4	KCNH2, SCN5A
DARUNAVIR	4	KCNH2, SCN5A
DARIFENACIN	4	KCNH2, SCN5A
BENZONATATE	4	SCN5A
TOLTERODINE	4	KCNH2, SCN5A
RANOLAZINE	4	KCNH2, SCN5A
PIMOZIDE	4	KCNH2, SCN5A
NIMODIPINE	4	SCN5A
FELODIPINE	4	SCN5A
NICARDIPINE	4	KCNH2, SCN5A
AMLODIPINE	4	KCNH2, SCN5A
PHENYTOIN	4	KCNH2, SCN5A
PALIPERIDONE	4	KCNH2, SCN5A

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
KCNH2	4,851	Binding:3558, Toxicity:1071, Functional:169, ADMET:53
SCN5A	594	Binding:380, Functional:98, ADMET:72, Toxicity:43, Unclassified:1
RYR2	15	Binding:15
TNNI3	2	Binding:2
TTN	1	Binding:1
TMEM43	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
TTN	2.7.11.1	non-specific serine/threonine protein kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
SCN5A	594
KCNH2	4,851

Pharmacogenomics

Cohort genes with a PharmGKB record: 7; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
BEPRIDIL	4	KCNH2, SCN5A
CANDESARTAN CILEXETIL	4	SCN5A
TELMISARTAN	4	SCN5A
CARBAMAZEPINE	4	SCN5A
DIBUCAINE	4	KCNH2, SCN5A
IMIPRAMINE	4	KCNH2, SCN5A
DROPERIDOL	4	KCNH2, SCN5A
PONATINIB	4	KCNH2, SCN5A
DULOXETINE	4	KCNH2, SCN5A
PALONOSETRON	4	KCNH2, SCN5A
VILANTEROL	4	SCN5A
MEXILETINE HYDROCHLORIDE	4	SCN5A
UNOPROSTONE ISOPROPYL	4	SCN5A
LURASIDONE	4	KCNH2, SCN5A
LETERMOVIR	4	SCN5A
SERTINDOLE	4	KCNH2, SCN5A
FEDRATINIB	4	KCNH2, SCN5A
QUINIDINE	4	KCNH2, SCN5A
DARUNAVIR	4	KCNH2, SCN5A
DARIFENACIN	4	KCNH2, SCN5A
BENZONATATE	4	SCN5A
TOLTERODINE	4	KCNH2, SCN5A
RANOLAZINE	4	KCNH2, SCN5A
PIMOZIDE	4	KCNH2, SCN5A
NIMODIPINE	4	SCN5A
FELODIPINE	4	SCN5A
NICARDIPINE	4	KCNH2, SCN5A
AMLODIPINE	4	KCNH2, SCN5A
PHENYTOIN	4	KCNH2, SCN5A
PALIPERIDONE	4	KCNH2, SCN5A

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	SCN5A, KCNH2
B	Phased (≥1) drug, not yet approved	1	RYR2
C	Druggable family + PDB, no drug	1	TTN
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	3	TNNI3, TMEM43, ANK2

Undrugged target profiles

4 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
TNNI3	2	—
TTN	1	—
TMEM43	1	—
ANK2	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 47.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	42
PHASE4	2
PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03826524	PHASE4	RECRUITING	Epinephrine Dose: Optimal Versus Standard Evaluation Trial
NCT01377337	PHASE4	UNKNOWN	Sodium Bicarbonate in Cardiopulmonary Resuscitation
NCT01521208	PHASE3	UNKNOWN	LUCAS Chest Compressor Versus Manual Chest Compression in Out-of-hospital Sudden Cardiac Arrest. LUCAT Trial
NCT01319110	PHASE2	COMPLETED	Coenzyme Q10 in Post-Cardiac Arrest Cerebral Resuscitation
NCT00226681	PHASE1	COMPLETED	Nurses Helping Sudden Cardiac Arrest Survivors Recover After Getting An Implantable Cardioverter Defibrillator (ICD)
NCT03049254	Not specified	RECRUITING	Mayo AVC Registry and Biobank
NCT03493516	Not specified	ACTIVE_NOT_RECRUITING	Prediction of ARrhythmic Events With Positron Emission Tomography II
NCT04189822	Not specified	ENROLLING_BY_INVITATION	Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank
NCT04250857	Not specified	RECRUITING	HeartStart FRx Defibrillator Event Registry
NCT04493970	Not specified	RECRUITING	HS Students Mandatory Universal Student Instruction in CPR Appraised Learning- Is the Mandate Working?
NCT04840797	Not specified	RECRUITING	HeartStart HS1 Defibrillator* Event Registry
NCT05135403	Not specified	RECRUITING	ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)
NCT05855135	Not specified	ACTIVE_NOT_RECRUITING	Assessment of Combined CCM and ICD Device in HFrEF
NCT06229418	Not specified	RECRUITING	Developing and Testing Drone-Delivered AEDs for Cardiac Arrests In Rural America
NCT06642168	Not specified	RECRUITING	Sudden Cardiac Arrest Related to Sport in Young and Value of the Genetic Assessment: a French Prospective Register
NCT06804499	Not specified	RECRUITING	Tampere Coronary Artery Disease and Sudden Cardiac Arrest Study
NCT06805344	Not specified	NOT_YET_RECRUITING	The OSIRIS ECPR Trial
NCT06948266	Not specified	ACTIVE_NOT_RECRUITING	The Study Aims to Investigate the Frequency and Clinical Characteristics of Out-of-hospital Cardiac Arrests (OHCA) Occurring in Poland in 2023. This Research Seeks to Provide a Comprehensive Analysis of OHCA Incidents Across the Country, Focusing on Their Prevalence and the Associated Clinical fe
NCT07014579	Not specified	NOT_YET_RECRUITING	Using Heart Electrical Signals to Study How Well Treatments Prevent Dangerous Heart Rhythms in Active People
NCT07331831	Not specified	ENROLLING_BY_INVITATION	Research on Attitudes, Confidence, and Practical Skills in Performing Cardiopulmonary Resuscitation and Automated External Defibrillation After Completing a Course Based on the European Resuscitation Council Model
NCT07444931	Not specified	RECRUITING	Validation of Sudden Cardiac Arrest Risk Factors in Patients With CAD
NCT07452016	Not specified	NOT_YET_RECRUITING	AI-guided Prediction and Treatment of Cardiac Arrest
NCT07596446	Not specified	RECRUITING	FEMART-1 Pilot Study
NCT00918125	Not specified	COMPLETED	Educational Videos to Improve Patient Decision Making and Race Disparities in Implantable Cardioverter Defibrillator Use
NCT01038440	Not specified	COMPLETED	Time and Dose Evaluation of Stearidonic Acid (SDA) to Eicosapentaenoic Acid (EPA) in Red Blood Cells
NCT01326624	Not specified	COMPLETED	Study of the Wearable Defibrillator in Heart-Failure Patients
NCT01749202	Not specified	COMPLETED	Effects of Stearidonic Acid-Containing Foods on Eicosapentaenoic Acid Levels in Red Blood Cells and Omega-3 Index
NCT01809652	Not specified	COMPLETED	Feasibility Study of Remote Support for Implantable Pulse Generator (IPG)/Implantable Cardioverter Defibrillator (ICD) Implant
NCT01822145	Not specified	UNKNOWN	A Feasibility Study on Prediction of an ICD Shock by ICD-derived Data
NCT02099721	Not specified	COMPLETED	Improve Sudden Cardiac Arrest Study
NCT02349087	Not specified	TERMINATED	EEG in Resuscitated In-hospital Patients
NCT02481206	Not specified	TERMINATED	Wearable Cardioverter Defibrillator in Hemodialysis Patients (WED-HED) Study
NCT02816047	Not specified	UNKNOWN	Austrian Wearable Cardioverter Defibrillator Registry
NCT02874469	Not specified	COMPLETED	Impact of an Intensive Care Diary on Post-traumatic Stress Disorder After a Resuscitated Sudden Death
NCT03016754	Not specified	COMPLETED	Heart Failure Optimization Study
NCT03065647	Not specified	COMPLETED	ECPR for Refractory Out-Of-Hospital Cardiac Arrest
NCT03642587	Not specified	COMPLETED	Canadian Sudden Cardiac Arrest Network
NCT03715790	Not specified	COMPLETED	Improve SCA Bridge Study
NCT04548804	Not specified	UNKNOWN	Better Mechanistic Understanding of and Risk Stratification for Ventricular Tachyarrhythmias Through ECGI
NCT05201495	Not specified	COMPLETED	The Jewel IDE Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
EPINEPHRINE	4	1
SAFFLOWER OIL	4	1
SODIUM BICARBONATE	4	1
UBIDECARENONE	3	1
RACEPINEPHRINE	2	1